{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:21Z","timestamp":1790392161466,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Although induction chemotherapy (IC) is the standard of care in medically fit patients with newly diagnosed acute myeloid leukemia (AML), limited retrospective data indicate that patients at adverse-risk may benefit from azacytidine and venetoclax (aza-ven). Our goal was to perform a Markov decision analysis to determine whether IC or aza-ven is the optimal induction regimen in this population. Using the TreeAge software, Markov models were created for adverse-risk and intermediate-risk cohorts. A systematic review of the literature informed the transition probabilities and utilities included in the analyses. Our primary outcome was quality-adjusted life years (QALYs) gained over 5 years after diagnosis. Overall, patients at adverse risk treated with IC gained 1.4 QALYs, compared with 2.0 QALYs in patients treated with aza-ven. Patients at adverse risk treated with IC and allogeneic stem cell transplantation (allo-SCT), IC, aza-ven and allo-SCT, or aza-ven gained 2.1, 1.5, 3.0, and 1.9 QALYs, respectively. Meanwhile, patients at intermediate risk treated with IC gained 2.0 QALY, compared with 1.7 QALY in patients treated with aza-ven. Patients at intermediate risk treated with IC and allo-SCT, IC, aza-ven and allo-SCT, and aza-ven gained 2.7, 2.3, 2.6, and 1.8 QALYs, respectively. We have demonstrated that medically fit patients with newly diagnosed adverse-risk AML may benefit from treatment with aza-ven over those treated with IC, whereas IC remains the preferred approach for patients at intermediate risk. Our work challenges the use of the European LeukemiaNet risk classification for patients treated with aza-ven and highlights the need for prospective investigation into aza-ven as induction therapy for medically fit patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011219","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T21:11:16Z","timestamp":1701292276000},"page":"629-639","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML"],"prefix":"10.1182","volume":"8","author":[{"given":"Mithunan","family":"Ravindran","sequence":"first","affiliation":[{"name":"1Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-3849","authenticated-orcid":false,"given":"Lee","family":"Mozessohn","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"2Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cheung","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"2Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"2Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7538-5772","authenticated-orcid":false,"given":"Jennifer","family":"Teichman","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"2Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"issue":"2","key":"2024021217050207000_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024021217050207000_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024021217050207000_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","article-title":"Frailty and the management of hematologic malignancies","volume":"131","author":"Abel","year":"2018","journal-title":"Blood"},{"key":"2024021217050207000_bib4","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program\n          . Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML). National Cancer Institute. Accessed 20 December 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"1","key":"2024021217050207000_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2024021217050207000_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024021217050207000_bib7","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024021217050207000_bib8","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2022-162525","article-title":"A\u00a0phase 2 randomized study comparing venetoclax and azacitidine to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"140","author":"Fathi","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024021217050207000_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"issue":"2","key":"2024021217050207000_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A\u00a0decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2024021217050207000_bib11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2010-05-285502","article-title":"A\u00a0Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission","volume":"117","author":"Kurosawa","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2024021217050207000_bib12","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"15","key":"2024021217050207000_bib13","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1182\/bloodadvances.2023010108","article-title":"Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations","volume":"7","author":"Slot","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024021217050207000_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2024021217050207000_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2024021217050207000_bib16","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024021217050207000_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2024021217050207000_bib18","doi-asserted-by":"crossref","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax\u00a0+ azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2024021217050207000_bib19","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/bjh.17996","article-title":"Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia","volume":"196","author":"Salhotra","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"2024021217050207000_bib20","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"issue":"suppl 1","key":"2024021217050207000_bib21","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood-2022-167967","article-title":"Molecular predictors of response and survival in patients with relapsed\/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy","volume":"140","author":"Johnson","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024021217050207000_bib22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","article-title":"European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol","volume":"6","author":"Bataller","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2024021217050207000_bib23","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2024021217050207000_bib24","doi-asserted-by":"crossref","first-page":"256.e1","DOI":"10.1016\/j.jtct.2020.12.021","article-title":"ELN 2017 Genetic Risk Stratification predicts survival of acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Hansen","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2024021217050207000_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024021217050207000_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2022-168522","article-title":"Prognostic relevance of adult acute myeloid leukemia patients according to the 2022 European Leukemianet Risk Stratification","volume":"140","author":"Lo","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024021217050207000_bib27","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1182\/blood-2022-167022","article-title":"Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia","volume":"140","author":"Rausch","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024021217050207000_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"issue":"2","key":"2024021217050207000_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2024021217050207000_bib30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"key":"2024021217050207000_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12962-018-0153-4","article-title":"Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom","volume":"16","author":"Tremblay","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"2024021217050207000_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"2024021217050207000_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"8","key":"2024021217050207000_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-022-01145-7","article-title":"Cost-effectiveness analysis of venetoclax in combination with azacitidine versus azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a US third party payer perspective","volume":"40","author":"Pratz","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"2024021217050207000_bib35","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.3390\/curroncol29100592","article-title":"Venetoclax in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia: a canadian cost-utility analysis","volume":"29","author":"Guinan","year":"2022","journal-title":"Curr Oncol"},{"issue":"12","key":"2024021217050207000_bib36","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"2024021217050207000_bib37","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaoncol.2019.0902","article-title":"Revised acute myeloid leukemia composite model using the 2017 European LeukemiaNet risk classification","volume":"5","author":"Sorror","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"2024021217050207000_bib38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024021217050207000_bib39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2024021217050207000_bib40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024021217050207000_bib41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2010.267","article-title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Chou","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2024021217050207000_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-022-01339-8","article-title":"Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation","volume":"15","author":"Kunadt","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"22","key":"2024021217050207000_bib43","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024021217050207000_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/ejh.12271","article-title":"IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation","volume":"92","author":"Yamaguchi","year":"2014","journal-title":"Eur J Haematol"},{"issue":"12","key":"2024021217050207000_bib45","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"2024021217050207000_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","volume":"5","author":"Chotirat","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"13","key":"2024021217050207000_bib47","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2024021217050207000_bib48","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in -mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024021217050207000_bib49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024021217050207000_bib50","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024021217050207000_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/629\/2212835\/blooda_adv-2023-011219-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/629\/2212835\/blooda_adv-2023-011219-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T17:05:37Z","timestamp":1707757537000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/3\/629\/506339\/A-Markov-analysis-of-azacitidine-and-venetoclax-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011219","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}